Atrial Fibrillation Market Expected to Experience Major Growth by 2032, According to DelveInsight | Anthos Therapeutics, ARCA biopharma, AbbVie, Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical

The Atrial Fibrillation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atrial Fibrillation pipeline products will significantly revolutionize the Atrial Fibrillation market dynamics.

DelveInsight's "Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Atrial Fibrillation market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Atrial Fibrillation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atrial Fibrillation Market Insights
https://www.delveinsight.com/sample-request/atrial-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Atrial Fibrillation Market Report:
• The Atrial Fibrillation market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2025, CardioFocus, Inc., a medical device company specializing in ablation therapies for cardiac arrhythmias, has shared the 12-month outcomes from its ECLIPSE AF trial, published in Circulation: Arrhythmia & Electrophysiology. The study demonstrated that 90.2% of patients with paroxysmal atrial fibrillation (AF) remained free from clinically significant atrial arrhythmias one year after undergoing de novo pulmonary vein isolation (PVI). This result was achieved through the use of three commercially available contact-force sensing focal catheters in combination with the CentauriTM System's advanced WAVE1TM pulsed field ablation (PFA) waveform.
• In January 2025, Boston Scientific Corporation (NYSE: BSX) has shared new data backing the use of both the FARAPULSETM Pulsed Field Ablation (PFA) System* and the WATCHMAN FLXTM Left Atrial Appendage Closure (LAAC) Device at the AF Symposium 2025 during a late-breaking science session. The session also featured a predefined sub-analysis from the OPTION clinical trial, which expanded on the favorable primary endpoint outcomes previously presented at the American Heart Association 2024 conference and published in The New England Journal of Medicine. The analysis involved 1,600 atrial fibrillation patients who received device implantation either at the time of ablation or 90-180 days later, supporting the 36-month findings comparing the WATCHMAN FLX with direct oral anticoagulants (mostly DOACs)
• In January 2025, The initial phase of the ADVANTAGE AF clinical trial has achieved its safety and efficacy goals in treating drug-resistant, symptomatic, persistent atrial fibrillation using the FARAPULSETM Pulsed Field Ablation (PFA) System. While the FARAPULSE PFA System is currently approved for pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation-where irregular heart rhythms occur intermittently and typically resolve on their own-this study assessed its use for both PVI and posterior wall ablation (PWA) in those with persistent atrial fibrillation. This form of AF lasts longer than seven days and represents about 25% of all AF cases. The prospective, single-arm trial included 260 patients across 43 international sites who were unresponsive to at least one Class I or III anti-arrhythmic drug.
• In October 2024, Abbott has reached two significant milestones in its clinical trials evaluating its pulsed field ablation (PFA) technology for managing irregular heart rhythms. The first milestone involved the early completion of patient enrollment in the VOLT-AF study. Abbott confirmed that enrollment concluded ahead of schedule. This study, conducted under an investigational device exemption (IDE), is designed to assess the effectiveness of Abbott's VOLT PFA system in treating atrial fibrillation (AF).
• According to the study conducted by Rosenthal et al. 2016, Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. It affects more than 2.7 to 6.1 million persons in the United States
• According to a study by Chung et al., 2021, in the UK, there are an estimated 1.5 million individuals living with Atrial Fibrillation, similar to the number of people with MI and exceeding those of cerebrovascular diseases and heart failure in 2020.
• Key Atrial Fibrillation Companies: Anthos Therapeutics, ARCA biopharma, AbbVie, Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, HUYA Bioscience, Novartis, Acesion Pharma, and others, and others
• Key Atrial Fibrillation Therapies: MAA868, HBI-3000, and others
• The Atrial Fibrillation epidemiology based on gender analyzed that Atrial fibrillation affects males more than females

Atrial Fibrillation Overview
Atrial Fibrillation (AF) is an abnormal heart rhythm (arrhythmia) characterized by the rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain.

Get a Free sample for the Atrial Fibrillation Market Report -
https://www.delveinsight.com/report-store/atrial-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atrial Fibrillation Market
The dynamics of the Atrial Fibrillation market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Atrial Fibrillation Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Atrial Fibrillation Epidemiology Segmentation:
The Atrial Fibrillation market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Atrial Fibrillation
• Prevalent Cases of Atrial Fibrillation by severity
• Gender-specific Prevalence of Atrial Fibrillation
• Diagnosed Cases of Episodic and Chronic Atrial Fibrillation

Download the report to understand which factors are driving Atrial Fibrillation epidemiology trends @ Atrial Fibrillation Epidemiological Insights
https://www.delveinsight.com/sample-request/atrial-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atrial Fibrillation Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atrial Fibrillation market or expected to get launched during the study period. The analysis covers Atrial Fibrillation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Atrial Fibrillation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atrial Fibrillation Therapies and Key Companies
• MAA868: Anthos Therapeutics
• HBI-3000: HUYABIO International

To know more about Atrial Fibrillation treatment, visit @ Atrial Fibrillation Medications
https://www.delveinsight.com/sample-request/atrial-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Atrial Fibrillation Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Atrial Fibrillation Companies: Anthos Therapeutics, ARCA biopharma, AbbVie, Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, HUYA Bioscience, Novartis, Acesion Pharma, and others, and others
• Key Atrial Fibrillation Therapies: MAA868, HBI-3000, and others
• Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
• Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Atrial Fibrillation Unmet Needs, KOL's views, Analyst's views, Atrial Fibrillation Market Access and Reimbursement

Discover more about therapies set to grab major Atrial Fibrillation market share @ Atrial Fibrillation Treatment Landscape
https://www.delveinsight.com/sample-request/atrial-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Atrial Fibrillation Market Report Introduction
2. Executive Summary for Atrial Fibrillation
3. SWOT analysis of Atrial Fibrillation
4. Atrial Fibrillation Patient Share (%) Overview at a Glance
5. Atrial Fibrillation Market Overview at a Glance
6. Atrial Fibrillation Disease Background and Overview
7. Atrial Fibrillation Epidemiology and Patient Population
8. Country-Specific Patient Population of Atrial Fibrillation
9. Atrial Fibrillation Current Treatment and Medical Practices
10. Atrial Fibrillation Unmet Needs
11. Atrial Fibrillation Emerging Therapies
12. Atrial Fibrillation Market Outlook
13. Country-Wise Atrial Fibrillation Market Analysis (2019-2032)
14. Atrial Fibrillation Market Access and Reimbursement of Therapies
15. Atrial Fibrillation Market Drivers
16. Atrial Fibrillation Market Barriers
17. Atrial Fibrillation Appendix
18. Atrial Fibrillation Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight


Related Reports:

Atrial Fibrillation Epidemiology https://www.delveinsight.com/report-store/atrial-fibrillation-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atrial Fibrillation Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Atrial Fibrillation epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market
• Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market
• Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.